Smruthi Organics Ltd

Smruthi Organics Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 August 2026, providing investors with the latest insights into the company’s performance and outlook.

Smruthi Organics Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair valuation grade. This change reflects evolving market perceptions amid mixed financial metrics and competitive pressures, prompting a downgrade in its Mojo Grade from Hold to Sell as of 16 July 2026.

Smruthi Organics Ltd is rated Sell by MarketsMOJO, with this rating last updated on 16 July 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 28 July 2026, providing investors with the latest insights into its performance and outlook.

Smruthi Organics Ltd has seen its investment rating downgraded from Hold to Sell, reflecting a combination of deteriorating technical indicators, flat financial performance, and subdued long-term growth prospects. The micro-cap pharmaceutical company’s Mojo Score has declined to 42.0, signalling caution for investors amid ongoing underperformance relative to benchmarks and peers.

Smruthi Organics Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 7 July 2026. This change reflects a nuanced improvement across technical indicators, valuation metrics, and financial stability, despite ongoing challenges in long-term growth and recent flat quarterly performance.

Smruthi Organics Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 29 June 2026. This revision reflects a combination of deteriorating financial trends, subdued quality metrics, and a shift in technical indicators, despite some valuation attractiveness. The company’s Mojo Score now stands at 48.0, signalling caution for investors amid a challenging operating environment.

Smruthi Organics Ltd has seen its investment rating upgraded from Sell to Hold as of 22 June 2026, reflecting a nuanced improvement across technical indicators, valuation metrics, and financial stability despite ongoing challenges in long-term growth. The micro-cap pharmaceutical company’s Mojo Score rose to 58.0, signalling a cautious but positive shift in investor sentiment.

Smruthi Organics Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 15 June 2026. This change reflects a combination of deteriorating technical indicators, a shift to a more attractive yet cautionary valuation, flat financial trends, and subdued quality metrics, signalling increased risk for investors amid challenging market conditions.

Smruthi Organics Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters shift favourably, moving from a fair to an attractive rating. Despite a recent dip in share price and sector headwinds, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present a compelling case for investors seeking value in a challenging market environment.

Smruthi Organics Ltd has seen its investment rating upgraded from Sell to Hold as of 8 June 2026, reflecting a nuanced shift in the company’s overall outlook. This change is driven by a combination of factors including improved debt servicing ability, fair valuation metrics, and a stabilising financial trend, despite ongoing challenges in long-term growth and market performance.

Smruthi Organics Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 3 June 2026. This revision reflects a combination of deteriorating technical indicators, subdued financial trends, and valuation concerns, signalling caution for investors amid persistent underperformance against benchmarks.

Smruthi Organics Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 29 May 2026. This change reflects a nuanced improvement across technical indicators, valuation metrics, financial trends, and overall quality assessment, signalling a cautious but more optimistic outlook for investors.

Smruthi Organics Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 May 2026, providing investors with the latest insights into its performance and outlook.

Smruthi Organics Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a flat financial performance for the quarter ended March 2026, signalling a notable shift from its previously positive growth trajectory. Despite a higher profit after tax (PAT) for the nine-month period, the company’s net sales have contracted sharply, prompting a downgrade in its Mojo Grade from Hold to Sell.

Smruthi Organics Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹130.00 crores, reported a sequential recovery in profitability for the quarter ending March 2026, though the underlying revenue trends remain concerning. Net profit for Q4 FY26 stood at ₹1.07 crores, marking a decline of 23.60% quarter-on-quarter from ₹1.40 crores in Q3 FY26, whilst representing a sharp 52.02% decline year-on-year from ₹2.23 crores in Q4 FY25.

Smruthi Organics Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 12 May 2026. This shift reflects a combination of deteriorating technical indicators, subdued long-term financial growth, and valuation concerns despite some recent positive earnings momentum. The company’s Mojo Score now stands at 48.0, signalling caution for investors amid a challenging market backdrop.